ARFXF News and Press, Amorfix Life Sciences Ltd From 03/27/19

POINT ROBERTS, Wash. and DELTA, British Columbia, March 27, 2019 (GLOBE NEWSWIRE) -- Investorideas.com , a leading investor news resource covering biotech and pharma stocks releases a snapshot looking at the biopharmaceutical market and how monoclonal antibody research is gaining market ...

ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019 Canada NewsWire TORONTO and CAMBRIDGE, MA, March 26, 2019 Company to showcase innovative programs addressing urgent need for disease-modifying therapies selectively targeting toxic oligomers in Alzh...

Thinly traded nano cap ProMIS Neurosciences ( OTCQB:ARFXF -23.5% ) is down on almost a 9x surge in volume in apparent sympathy with the drop in Biogen and Eisai after they terminated development of Alzheimer's candidate aducanumab, an amyloid beta-targeting monoclonal antibody. More ne...

Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease Canada NewsWire TORONTO and CAMBRIDGE, MA, March 21, 2019 Discontinued aducanumab phase 3 studies emphasize urgent need for therapies that target the  tox...

Selected for podium presentation: novel antibody candidates bind only the toxic species of alpha-synuclein offering potential advantages over less selective therapies in development  TORONTO and CAMBRIDGE, MA , March 19, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN...

ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results Canada NewsWire TORONTO, ON and CAMBRIDGE, MA, March 15, 2019 TORONTO , ON and CAMBRIDGE, MA , March 15, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused...

ProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors Canada NewsWire TORONTO and CAMBRIDGE, MA, Feb. 21, 2019 Former Sanofi U.S. Chairman to provide guidance and assistance to ProMIS business development strategies and partnering pla...

Parkinson's Disease: ProMIS Neurosciences Identifies Several Antibody Drug Candidates Showing Best-in-Class Selectivity for Toxic Forms of Alpha-Synuclein Compared to other Therapeutic Antibodies in Development Canada NewsWire TORONTO and CAMBRIDGE, MA, Feb. 12, 2019 Compet...

Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease Canada NewsWire TORONTO and CAMBRIDGE, MA, Jan. 31, 2019 Discontinued crenezumab phase 3 studies underscore urgent need for therapies that target the  toxic oligomer with extrao...

ProMIS Neurosciences ( OTCQB:ARFXF ) has closed a private placement of 9.56M Units at a price of C$0.23 (or $0.173) per Unit for gross proceeds of ~C$2,198,800. More news on: Promis Neurosciences Inc, Healthcare stocks news, Read more ...